NCT00520091View on ClinicalTrials.gov

Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

September 30, 2010

Conditions
Esophageal Cancer
Interventions
DRUG

CPT- 11

65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery

DRUG

Cisplatin

Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery

DRUG

Celecoxib

400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin

RADIATION

Radiation

4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks

PROCEDURE

Surgery

Surgery will occur prior to chemoradiation therapy for those patients with resectable disease

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT00520091 - Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer | Biotech Hunter | Biotech Hunter